A Phase 1, Open-Label, Randomized Study of Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
Latest Information Update: 03 Jan 2025
Price :
$35 *
At a glance
- Drugs Axatilimab (Primary) ; Axatilimab (Primary)
- Indications Cholangiocarcinoma; Graft-versus-host disease; Hodgkin's disease; Idiopathic pulmonary fibrosis; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Incyte Corporation
- 30 Dec 2024 Status changed from not yet recruiting to recruiting.
- 06 Dec 2024 New trial record